

Antibody Characterization Report for Leucine-rich repeat kinase 2 (LRRK2)

YCharOS Antibody Characterization Report

Author(s): Riham Ayoubi¹, Maryam Fotouhi¹, Joel Ryan², Wolfgang Reintsch³, Sara González Bolívar¹, Thomas M. Durcan³, Claire M. Brown², Peter S. McPherson¹ and Carl Laflamme^{1*}

¹ Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

² Advanced BiImaging Facility (ABIF), McGill University, Montreal, Canada

³ The Neuro's Early Drug Discovery Unit (EDDU), Structural Genomics Consortium, McGill University, Montreal, Quebec, Canada

* Corresponding author: carl.laflamme@mcgill.ca

Target:

Recommended protein name: Leucine-rich repeat serine/threonine-protein kinase 2

Short protein name: Leucine-rich repeat kinase 2

Alternative protein name: Dardarin

Gene name: *LRRK2*

Uniprot: Q5S007

We are a third-party organization with the mission to characterize commercial antibodies for all human protein through open science [1]. In this study, we characterized 13 Leucine-rich repeat kinase 2 commercial antibodies for Western Blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol [2] based on comparing read-outs in knockout cell lines and isogenic parental controls. We identified many well-performing antibodies and encourage readers to use this report as a guide to select the most appropriate antibody for their specific needs.

The A549 *LRRK2* KO line was kindly donated by Dr. Dario Alessi (University of Dundee).

The authors do not provide an assessment of the quality of the tested antibodies as their respective performances are limited to our finite experimental conditions. The readers should interpret the present findings based on their own scientific expertise. The authors acknowledge that an antibody that demonstrates specificity in the stated test conditions can be suboptimal in a different experimental format or in cell lines that differ from those directly tested here.

Table 1: Summary of the cell lines used

Institution	Catalog number	RRID (Cellosaurus)	Cell line	Genotype
ATCC	CCL-185	CVCL_0023	A549	WT
Academic partner	-	-	A549	<i>LRRK2</i> KO

Table 2: Summary of the Leucine-rich repeat kinase 2 antibodies tested

Company	Catalog number	Lot number	RRID (Antibody Registry)	Clonality	Clone ID	Host	Concentration (µg/µl)	Vendors recommended applications
Abcam	ab133474**	GR3445288-1	AB_2713963	recombinant-mono	MJFF2 (c41-2)	rabbit	0.651	Wb,IP,IF
Abcam	ab133475**	GR3425439-3	AB_2620136	recombinant-mono	MJFF3 (c69-6)	rabbit	0.119	Wb
Abcam	ab133476**	GR97391-10	n/a	recombinant-mono	MJFF4 (c81-8)	rabbit	0.085	Wb
Abcam	ab133518**	GR3380028-3	n/a	recombinant-mono	UDD3 30(12)	rabbit	2.169	Wb,IF
Abcam	ab181386**	GR3395422-1	n/a	recombinant-mono	MJFF5 (68-7)	rabbit	0.614	Wb
Abcam	ab1863348*	GR206786-20	n/a	monoclonal	N138/6	mouse	1	Wb,IF
ABclonal	A17253	3561314002	AB_2770220	polyclonal	-	rabbit	2.03	Wb,IF
Cell Signaling Technology	13046**	3	n/a	recombinant-mono	D18E12	rabbit	1.095	Wb,IP
Cell Signaling Technology	36408*	1	n/a	monoclonal	E8Z7T	mouse	0.025	[others]
GeneTex	GTX113067	40408	AB_10722180	polyclonal	-	rabbit	1	Wb,IF
Thermo Fisher Scientific	MA5-11154*	XF3612571	AB_10982994	monoclonal	133AT1218	mouse	0.45	Wb
Thermo Fisher Scientific	MA5-111558*	XF3612572	AB_2297138	monoclonal	133AT720	mouse	0.5	Wb
Thermo Fisher Scientific	PA5-85363	XF3611578E	AB_2792505	polyclonal	-	rabbit	1	Wb,IF

Wb=Western Blot, IP= immunoprecipitation, IF=immunofluorescence, *=monoclonal antibody, **=recombinant antibody

Materials and methods

Antibodies

All the Leucine-rich repeat kinase 2 antibodies tested are listed in Table 2. Peroxidase-conjugated goat anti-rabbit and anti-mouse are from Thermo Fisher Scientific (cat. number 65-6120 and 62-6520). Alexa-555-conjugated goat anti-rabbit and anti-mouse secondary antibodies are from Thermo Fisher Scientific (cat. number A21429 and A21424).

Cell culture

Cells were cultured in DMEM high glucose (GE Healthcare cat. number SH30081.01) containing 10% fetal bovine serum (Wisent, cat. number 080450), 2 mM L-glutamate (Wisent cat. number 609065, 100 IU penicillin and 100 µg/ml streptomycin (Wisent cat. number 450201).

Antibody screening by Western Blot

Western Blots were performed as described in our standard operating procedure [3]. A549 WT and *LRRK2* KO (listed in Table 1) were collected in RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) from Thermo Fisher Scientific (cat. number 89901) supplemented with 1x protease inhibitor cocktail mix (MilliporeSigma, cat. number 78429). Lysates were sonicated briefly and incubated 30 min on ice. Lysates were spun at ~110,000xg for 15 min at 4°C and equal protein aliquots of the supernatants were analyzed by SDS-PAGE and Western Blot. BLUelf prestained protein ladder from GeneDireX (cat. number PM008-0500) was used.

Western Blots were performed with precast midi 4-20% Tris-Glycine polyacrylamide gels from Thermo Fisher Scientific (cat. number WXP42012BOX) ran with Tris/Glycine/SDS buffer from bio-Rad (cat. number 1610772), loaded in Laemmli loading sample buffer from Thermo Fisher Scientific (cat. number AAJ61337AD) and transferred on nitrocellulose membranes. Proteins on the blots were visualized with Ponceau S staining (Thermo Fisher Scientific, cat. number BP103-10) which is scanned to show together with individual Western Blot. Blots were blocked with 5% milk for 1 hr, and antibodies were incubated O/N at 4°C with 5% milk in TBS with 0,1% Tween 20 (TBST) from Cell Signaling (cat. number 9997). Following three washes with TBST, the peroxidase conjugated secondary antibody was incubated at a dilution of ~0.2 µg/ml in TBST with 5% milk for 1 hr at room temperature followed by three washes with TBST. Membranes were incubated with Pierce ECL from Thermo Fisher Scientific (cat. number 32106)

or Clarity Western ECL Substrate from Bio-Rad (cat. number 1705061) prior to detection with the iBright™ CL1500 Imaging System from Thermo Fisher Scientific (cat. number A44240).

Antibody screening by immunoprecipitation

Immunoprecipitation was performed as described in our standard operating procedure [4]. Antibody-beads conjugates were prepared by adding 2 to 500 µl of Pierce IP Lysis Buffer from Thermo Fisher Scientific (cat. number 87788) in a microcentrifuge tube, together with with 30µl of Dynabeads protein A- (for rabbit antibodies) or protein G- (for mouse antibodies) from Thermo Fisher Scientific (cat. number 10002D and 10004D, respectively). Tubes were rocked for ~1 hr at 4°C followed by two washes to remove unbound antibodies.

A549 WT were collected in Pierce IP buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol) supplemented with protease inhibitor. Lysates were rocked 30 min at 4°C and spun at 110,000xg for 15 min at 4°C. 0.5 ml aliquots at 2.0 mg/ml of lysate were incubated with an antibody-bead conjugate for ~1 hr at 4°C. The unbound fractions were collected, and beads were subsequently washed three times with 1.0 ml of IP lysis buffer and processed for SDS-PAGE and Western Blot on precast midi 4-20% Tris-Glycine polyacrylamide gels. Prot-A:HRP (MilliporeSigma, cat. number P8651) was used as a secondary detection system at a concentration of 0.3 µg/ml when a rabbit antibody was used for Western Blot. Anti-mouse IgG for IP (HRP) (Abcam, cat. number ab131368) was used as a secondary detection system at a concentration of 0.5 µg/ml when a mouse antibody was used for Western Blot.

Antibody screening by immunofluorescence

Immunofluorescence was performed as described in our standard operating procedure [5]. A549 WT and *LRRK2* KO were labelled with a green and a far-red fluorescence dye, respectively. The fluorescent dyes used are from Thermo Fisher Scientific (cat. number C2925 and C34565). WT and KO cells were plated in a 96-well plate with optically clear flat-bottom. (Perkin Elmer, cat. number 6055300) as a mosaic and incubated for 24 hrs in a cell culture incubator. Cells were fixed in 4% PFA (in PBS) for 15 min at room temperature and then washed 3 times with PBS. Cells were permeabilized in PBS with 0,1% Triton X-100 for 10 min at room temperature and blocked with PBS with 5% BSA, 5% goat serum and 0.01% Triton X-100 for 30 min at room temperature. Cells were incubated with IF buffer (PBS, 5% BSA, 0,01% Triton X-100) containing the primary Leucine-rich repeat kinase 2 antibodies O/N at 4°C. Cells were then washed 3 × 10 min with IF buffer and incubated with corresponding Alexa Fluor 555-

conjugated secondary antibodies in IF buffer at a dilution of 1.0 µg/ml for 1 hr at room temperature with DAPI. Cells were washed 3 × 10 min with IF buffer and once with PBS.

Images were acquired on an ImageXpress micro confocal high-content microscopy system (Molecular Devices), using a 20x NA 0.95 water immersion objective and scientific CMOS cameras, equipped with 395, 475, 555 and 635 nm solid state LED lights (lumencor Aura III light engine) and bandpass filters to excite DAPI, Cellmask Green, Alexa-555 and Cellmask Red, respectively. Images had pixel sizes of 0.68 x 0.68 microns, and a z-interval of 4 microns. For analysis and visualization, shading correction (shade only) was carried out for all images. Then, maximum intensity projections were generated using 3 z-slices. Segmentation was carried out separately on maximum intensity projections of Cellmask channels using CellPose 1.0, and masks were used to generate outlines and for intensity quantification. Figures were assembled with Adobe Illustrator.




Figure 1: Leucine-rich repeat kinase 2 antibody screening by Western Blot




Figure 2: Leucine-rich repeat kinase 2 antibody screening by immunoprecipitation




Figure 3: Leucine-rich repeat kinase 2 antibody screening by immunofluorescence (1/3)




Figure 3: Leucine-rich repeat kinase 2 antibody screening by immunofluorescence (2/3)




Figure 3: Leucine-rich repeat kinase 2 antibody screening by immunofluorescence (3/3)

Figure 1: Leucine-rich repeat kinase 2 antibody screening by Western Blot.

Lysates of A549 WT and *LRRK2* KO were prepared, and 25 µg of protein were processed for Western Blot with the indicated Leucine-rich repeat kinase 2 antibodies. The Ponceau stained transfers of each blot are shown. Antibody dilution used: ab133474** at 1/10 000, ab133475** at 1/1000, ab133476** at 1/500, ab133518** at 1/500, ab181386** at 1/500, ab186334* at 1/200, A17253 at 1/500, 13046** at 1/200, 36408* at 1/200, GTX113067 at 1/500, MA5-11154* at 1/200, MA5-111558* at 1/200, PA5-85363 at 1/500. Predicted band size: 286 kDa. *=monoclonal antibody, **=recombinant antibody

Figure 2: Leucine-rich repeat kinase 2 antibody screening by immunoprecipitation.

A549 lysates were prepared, and immunoprecipitation was performed using 2.0 µg of the indicated Leucine-rich repeat kinase 2 antibodies pre-coupled to Dynabeads protein A or protein G. Samples were washed and processed for Western Blot with the indicated Leucine-rich repeat kinase 2 antibody. For Western Blot, 36408* was used at 1/200 and ab133474** at 1/2000. The Ponceau stained transfers of each blot are shown. SM=4% starting material; UB=4% unbound fraction; IP=immunoprecipitate. *=monoclonal antibody, **=recombinant antibody

Figure 3: Leucine-rich repeat kinase 2 antibody screening by immunofluorescence.

A549 WT and *LRRK2* KO cells were labelled with a green or a far-red fluorescent dye, respectively. WT and KO cells were mixed and plated to a 1:1 ratio in a 96-well plate with optically clear flat-bottom. Cells were stained with the indicated Leucine-rich repeat kinase 2 antibodies and with the corresponding Alexa-fluor 555 coupled secondary antibody including DAPI. Acquisition of the blue (nucleus-DAPI), green (identification of WT cells), red (antibody staining) and far-red (identification of KO cells) channels was performed. Representative images of the blue and red (grayscale) channels are shown. WT and KO cells are outlined with green and magenta dashed line, respectively. Antibody dilution used: ab133474** at 1/100, ab133475** at 1/100, ab133476** at 1/80, ab133518** at 1/2000, ab181386** at 1/000, ab186334* at 1/100, A17253 at 1/200, 13046** at 1/100, 36408* at 1/000, GTX113067 at 1/500, MA5-11154* at 1/500, MA5-111558* at 1/500, PA5-85363 at 1/500. Bars = 10 µm. *=monoclonal antibody, **=recombinant antibody

References

1. Laflamme, C., et al., *Opinion: Independent third-party entities as a model for validation of commercial antibodies*. N Biotechnol, 2021. **65**: p. 1-8 DOI: 10.1016/j.nbt.2021.07.001.
2. Laflamme, C., et al., *Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72*. Elife, 2019. **8** DOI: 10.7554/eLife.48363.
3. Ayoubi, R., P.S. McPherson, and C. Laflamme, *Antibody Screening by Immunoblot*. 2021 DOI: <https://doi.org/10.5281/zenodo.5717510>.
4. Ayoubi, R., et al., *Antibody screening by Immunoprecipitation*. 2021 DOI: <https://doi.org/10.5281/zenodo.5717516>.
5. Alshafie, W., P. McPherson, and C. Laflamme, *Antibody screening by Immunofluorescence*. 2021 DOI: <https://doi.org/10.5281/zenodo.5717498>.